5e0i

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
m (Protected "5e0i" [edit=sysop:move=sysop])
Current revision (22:08, 28 June 2023) (edit) (undo)
 
(2 intermediate revisions not shown.)
Line 1: Line 1:
-
'''Unreleased structure'''
 
-
The entry 5e0i is ON HOLD
+
==Crystal structure of the HBV capsid Y132A mutant (VCID 8772) in complex with NVR10-001E2 at 1.95A resolution==
 +
<StructureSection load='5e0i' size='340' side='right'caption='[[5e0i]], [[Resolution|resolution]] 1.95&Aring;' scene=''>
 +
== Structural highlights ==
 +
<table><tr><td colspan='2'>[[5e0i]] is a 6 chain structure with sequence from [https://en.wikipedia.org/wiki/Hepatitis_B_virus_subtype_adyw Hepatitis B virus subtype adyw]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5E0I OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5E0I FirstGlance]. <br>
 +
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.95&#8491;</td></tr>
 +
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=5J6:METHYL+4-(2-BROMO-4-FLUOROPHENYL)-6-(MORPHOLIN-4-YLMETHYL)-2-(1,3-THIAZOL-2-YL)PYRIMIDINE-5-CARBOXYLATE'>5J6</scene></td></tr>
 +
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5e0i FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5e0i OCA], [https://pdbe.org/5e0i PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5e0i RCSB], [https://www.ebi.ac.uk/pdbsum/5e0i PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5e0i ProSAT]</span></td></tr>
 +
</table>
 +
== Function ==
 +
[https://www.uniprot.org/uniprot/CAPSD_HBVD1 CAPSD_HBVD1] Self assembles to form an icosahedral capsid. Most capsid appear to be large particles with a icosahedral symmetry of T=4 and consist of 240 copies of capsid protein, though a fraction forms smaller T=3 particles consisting of 180 capsid proteins. Entering capsid are transported along microtubules to the nucleus. Phosphorylation of the capsid is thought to induce exposure of nuclear localization signal in the C-terminal portion of the capsid protein that allows binding to the nuclear pore complex via the importin (karyopherin-) alpha and beta. Capsids are imported in intact form through the nuclear pore into the nuclear basket, where it probably binds NUP153. Only capsids that contain the mature viral genome can release the viral DNA and capsid protein into the nucleoplasm. Immature capsids get stucked in the basket. Capsids encapsulate the pre-genomic RNA and the P protein. Pre-genomic RNA is reverse transcribed into DNA while the capsid is still in the cytoplasm. The capsid can then either be directed to the nucleus, providing more genome for transcription, or bud through the endoplasmic reticulum to provide new virions (By similarity).<ref>PMID:7711014</ref> Encapsidates hepatitis delta genome (By similarity).<ref>PMID:7711014</ref>
 +
<div style="background-color:#fffaf0;">
 +
== Publication Abstract from PubMed ==
 +
The hepatitis B virus (HBV) core protein is essential for HBV replication and an important target for antiviral drug discovery. We report the first, to our knowledge, high-resolution crystal structure of an antiviral compound bound to the HBV core protein. The compound NVR-010-001-E2 can induce assembly of the HBV core wild-type and Y132A mutant proteins and thermostabilize the proteins with a Tm increase of more than 10 degrees C. NVR-010-001-E2 binds at the dimer-dimer interface of the core proteins, forms a new interaction surface promoting protein-protein interaction, induces protein assembly, and increases stability. The impact of naturally occurring core protein mutations on antiviral activity correlates with NVR-010-001-E2 binding interactions determined by crystallography. The crystal structure provides understanding of a drug efficacy mechanism related to the induction and stabilization of protein-protein interactions and enables structure-guided design to improve antiviral potency and drug-like properties.
-
Authors: Lukacs, C.M., Abendroth, J., Klumpp, K.
+
High-resolution crystal structure of a hepatitis B virus replication inhibitor bound to the viral core protein.,Klumpp K, Lam AM, Lukacs C, Vogel R, Ren S, Espiritu C, Baydo R, Atkins K, Abendroth J, Liao G, Efimov A, Hartman G, Flores OA Proc Natl Acad Sci U S A. 2015 Nov 23. pii: 201513803. PMID:26598693<ref>PMID:26598693</ref>
-
Description: Crystal structure of the HBV capsid Y132A mutant (VCID 8772) in cmoplex with NVR10-001E2 at 1.95A resolution
+
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
-
[[Category: Unreleased Structures]]
+
</div>
-
[[Category: Klumpp, K]]
+
<div class="pdbe-citations 5e0i" style="background-color:#fffaf0;"></div>
-
[[Category: Abendroth, J]]
+
== References ==
-
[[Category: Lukacs, C.M]]
+
<references/>
 +
__TOC__
 +
</StructureSection>
 +
[[Category: Hepatitis B virus subtype adyw]]
 +
[[Category: Large Structures]]
 +
[[Category: Abendroth J]]
 +
[[Category: Klumpp K]]
 +
[[Category: Lukacs CM]]

Current revision

Crystal structure of the HBV capsid Y132A mutant (VCID 8772) in complex with NVR10-001E2 at 1.95A resolution

PDB ID 5e0i

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/5e0i"
Personal tools